Navigation Links
Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
Date:12/10/2007

Strengthens DBI's Portfolio of Technologies for Enabling Faster, Easier Quantification of Protein Biomarkers in Translational Medicine and Adaptive

Clinical Trials

WALTHAM, Mass., Dec. 10 /PRNewswire/ -- Decision Biomarkers Inc (DBI), a leading developer of protein biomarker analysis systems for pharmaceutical research and development, today announced the company's PATH(R) technology has been awarded United States Patent 7,297,497 by the U.S. Patent and Trademark Office. The patent applies to a novel, ultra-thin nitrocellulose surface chemistry that enables the detection of low-abundance proteins. This technology is integrated into DBI's AVANTRA(TM)Q400 Biomarker Workstation, a new, easy-to-use, immunoassay system that enables non-specialized technicians to perform complex protein biomarker analyses in the lab or directly at a clinical trial site.

Protein microarray glass slides utilizing the PATH(R) technology are also available from leading life science consumable suppliers to enable researchers to perform ultra sensitive assays including sandwich immunoassays, capture immunoassays, protein profiling, and protein characterization.

"Nitrocellulose has proven to be the protein-assay substrate of choice for decades. With this technology, researchers can use a wide variety of fluorescence probes to make protein assays easier, faster and more sensitive than ever before," said Roger Dowd, CEO and President of DBI. "By delivering a high signal-to-noise ratio and low background fluorescence, we believe the PATH(R) surface chemistry to be far superior to other commercially available protein-array surfaces."

The AVANTRA(TM)Q400 Biomarker Workstation, DBI's flagship product, is commercially available with various protein biomarker content including "off-the-shelf" multiplex biomarker panels for oncology, immunology, and cardiology, along with custom content defined by the Company's collaborators.

About D
'/>"/>

SOURCE Decision Biomarkers Inc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision
2. Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
3. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
4. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
5. New Data Reveal Ethnicity May Play Role in Weight Loss Decisions
6. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
7. NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
8. Scientists Using Social Media to Inform Lab Purchasing Decisions
9. Ingenuity Systems Joins Biomarkers Consortium
10. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
11. Mirus Bio Awarded Grants & Contracts of Over $5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)HOUSTON, Dec. 3 JourneyLite of Houston, LLC announced today that it has updated its facility to offer patients a second surgical option, vertical sleeve gastrectomy , along with the LAP-BAND®
(Date:12/3/2009)DALLAS, Dec. 3 ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a deb
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/3/2009)WALTHAM, Mass., Dec. 3 Inverness Medical Innovations, Inc. (NYSE: IMA ), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and h
Breaking Biology Technology:JourneyLite of Houston Now Offering Sleeve Gastrectomy 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 2Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 3Access Pharmaceuticals Provides Update on MuGard Commercial Launch in Europe 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5
...Only U.S.-based Biorepositories Event for the Phar...ndustries, INDIANAPOLIS, June 23 BioStorage Tech...term biomaterials storage, sample,management and c...sponsorship of Institute for International Researc... U.S.-based event for the pharmaceutical and,biote...
...ON, N.J., June 23 Informed Medical Communications... forums for the,bio-pharmaceutical industry, today...cy and the appointment of Dr. Jaime Nguyen as Medi...specifically outlines the,role of the CO as well a...,training/education, internal monitoring/auditing,...
...YORK, June 23 Medicsight PLC, a,subsidiary of MGT...ndustry,leader in the development of Computer-Aide...ay announces that Allan Rowley (CFO) and Lucan Toh...ting at the Piper Jaffray,Third Annual Europe Conf... be held from 8:20 am to 4:00 pm at the ANdAZ,Lond...
Other Biology Technology:BioStorage Technologies Announces Platinum Sponsorship of Biorepositories 2008 2Informed Medical Communications Adopts Newly Enhanced Compliance Policy 2Medicsight to Present at Piper Jaffray Annual Europe Conference 2
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
(Date:12/3/2009)Forest dwellers must be included in the design of the upcoming forest deal at Copenhagen in order to avoid a humanitarian crisis, according to a scientist at the University of Leeds. , Writing today
(Date:12/3/2009)The 30-year record low in Antarctic snowmelt that occurred during the 2008-09 austral summer was likely due to concurrent strong positive phases for two main climate drivers, ENSO (El Nio - Southern O
Breaking Biology News(10 mins):Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Forest deal at Copenhagen must avoid creating 'carbon refugees' 2CCNY professor foresees rising Antarctic snowmelt 2Net32 Inc Reports Highest Customer Ratings Ever 56096 1Net32 Inc Reports Highest Customer Ratings Ever 56096 2NC State receives NSF grant to discover plant switchboards 9774 1NC State receives NSF grant to discover plant switchboards 9774 2NC State receives NSF grant to discover plant switchboards 9774 3NTU professor bags inaugural award honoring women in science 13812 1NTU professor bags inaugural award honoring women in science 13812 2NTU professor bags inaugural award honoring women in science 13812 3
... Food and Drug Administration is reconsidering the... study offers further evidence to support a Univer...e approach to asthma treatment may be in order. ...he University of Houston College of Pharmacy (UHCO...ceptor antagonist drugs (or beta blockers) ultimat...
...s have reported the first clinical evidence that g...matoid arthritis, an important milestone for this ...turbulent past. Described in the February issue of...m from a study of two patients with severe rheumat...nvestigator at Beth Israel Deaconess Medical Cente...
...inding that could save thousands of lives a year, ...have shown that a blood vessel disorder leading to...es, seizures, paralysis or other problems is treat...eople take to control high cholesterol. , If the ...t trial with people, statins could provide a safe,...
Other Biology News:New asthma research opposes current drug treatment, says UH prof 2New asthma research opposes current drug treatment, says UH prof 3New asthma research opposes current drug treatment, says UH prof 4Gene therapy demonstrates benefit in patients with rheumatoid arthritis 2Gene therapy demonstrates benefit in patients with rheumatoid arthritis 3Statins may treat blood vessel disorder that can lead to fatal strokes 2Statins may treat blood vessel disorder that can lead to fatal strokes 3
...pand the computing power of your ValveBank system!... a Macintosh computer using graphic 'click-and-dra...isk, print out program listings, then download you...le step., EasyCode is used for programming be...
Holten Safe 2010 Cabinet Model 0.9, with divided tabletop (230V / 50Hz) from Thermo Scientific
MSC.12 class II safety cabinet (Type A1) - CE Marked (120V / 60Hz) from Thermo Scientific
Fluoroskan Ascent, 100-240 V, 1 dispenser from Thermo Scientific
Biology Products: